ClinicalTrials.gg
RecruitingNCT07108868Updated Nov 6, 2026

A Phase I Dose Finding Study of MB-CART2219.1

A Phase 1 interventional study of CAR-T cells targeting CD19 and CD22 in Lymphoma, CLL and Acute Lymphoblastic Leukemia, Pediatric, sponsored by University Hospital Tuebingen. Recruiting at 2 sites in Germany. Open to participants aged 12 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-06.

Sponsored by University Hospital Tuebingen · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 4 months later.
Updated Nov 6, 2026Eligibility revisedStudy contact changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
12 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 144 studies in Lymphoma with a site in Germany — 15 open to participants now, 25 under way, 8 of them phase 3. Lymphoma · Germany.

Planned enrollment
103rd of 130
36 · median 114
Started
2025
with 3 others
Phase 1
19 of 144
1 open now
Primary completion
2027-03
later than 10 of 24 live
Registered
142nd of 144
by date

Among the 144 studies in Lymphoma with a site in Germany, this one is the 103rd largest by planned enrollment of the 130 interventional ones that give a count, is one of 4 that started in 2025, is one of 19 in phase 1, reaches primary completion later than 10 of the 24 other live ones, and was the 142nd registered.

Lymphoma

3,020 studies on the registry are indexed under Lymphoma; 434 are open to participants now.

Browse Lymphoma studies →

Open to participants now

15 of the 144 studies in Lymphoma with a site in Germany are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.

This study: 12 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 144 studies in Lymphoma with a site in Germany, or all of them as a file.
02

Study summary

A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies

03

Conditions studied

  • Lymphoma
  • CLL
  • Acute Lymphoblastic Leukemia, Pediatric

Keywords

  • MB-CART2219.1 targeting CD19/CD22
  • CD19/CD22
  • CAR-T cells
04

Who can participate

The criteria were revised on the registry on Nov 6, 2026. See what changed

Ages eligible
12 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For Cohort I Lymphoma, adults: Subject is ≥ 18 years of age at the time of signing the form (ICF).
  2. For Cohort II ALL, pediatric patients: Subject is ≥ 12-17 years of age at the time of signing ICF.
  3. Patient or legal guardian understand and voluntarily sign an informed consent document prior to any study related assessments/procedures.
  4. Able to adhere to the study visit schedule and other protocol requirements as well as agrees to continued follow up for up to 15 years as mandated by the regulatory guidelines for gene therapy trials.
  5. CD19 or CD22 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry. Results of previous assessments after the last treatment with CD19 targeted therapies but preceding inclusion of the patient in this trial are acceptable, if available.
  6. Female Subject of and male subjects with female partner of childbearing potential is willing to use highly effective methods during treatment until 12 months after IMP exposure.
  7. All subjects must agree to refrain from donating blood while on study drug and for 1 year after discontinuation from this study treatment.
  8. Male or female patients must have refractory (r/r) CD19 or CD22 -expressing ALL or Lymphoma/CLL and meet the following disease-specific criteria.

Cohort I: Lymphoma (Richter's Transformation /Burkitt lymphoma/NHL/CLL), Adults ≥18 years of age:

  • Disease entities: Patients with relapsed or refractory (r/r) B-cell lymphoid according to the WHO Classification of Haematolymphoid Tumours (5th edition), including:

    • B-lymphoblastic lymphoma
    • Chronic lymphocytic leukemia (CLL)
    • Splenic B-cell lymphoma
    • Marginal zone lymphoma
    • Follicular lymphoma
    • Mantle cell lymphoma
    • Diffuse large B-cell lymphoma (DLBCL) / Large B-cell lymphoma
    • Burkitt lymphoma
    • Transformed indolent B-cell lymphoma (including Richter's transformation)
  • Prior treatment and disease status: Patients must meet one of the following criteria:

    1. Relapsed or refractory disease after ≥2 prior systemic therapies, including at least one of the following (if clinically indicated and available):

      • Approved CAR-T cell therapy, or
      • Bispecific antibody therapy OR
    2. to CAR-T cell therapy and/or bispecific antibody therapy
  • CLL-specific: Patients with relapsed or refractory CLL:

    • After failure of established and approved treatment options
    • Including prior exposure to BTK inhibitor-based therapy
  • Transplant-related eligibility: Patients fulfilling at least one of the following:

    1. Indication for or allogeneic stem cell transplantation (SCT) as determined by a multidisciplinary board, but ineligible for SCT, or declining SCT after informed consent discussion
    2. Patients with refractory disease currently precluding alloSCT, including those considered for bridging to allogeneic SCT within the study framework
  • Post-transplant or post-targeted therapy relapse: Patients meeting at least one of the following:

    1. Relapse following autologous or allogeneic SCT
    2. Relapse following CD19- or CD22-directed therapy
    3. Confirmed expression of CD19 or CD22 at relapse
  • Central nervous system (CNS) involvement

    1. Patients with CNS involvement by lymphoma are eligible
    2. Provided that CNS disease is adequately controlled at the time of study inclusion Or

Cohort II: Acute B-lymphoplastic Leukemia (B-ALL), pediatric patients aged ≥ 12 - 17 years:

  • Patients with second or later relapse of ALL with >5% blasts in BM or rising molecular failure on two separate measurements and without an approved option for in label CAR-T cells or bispecific or cytotoxic antibody treatment.
  • Patients with relapse after SCT or other CD19 or CD22 targeted treatment with confirmed either CD19 or CD22 expression after relapse.
  • Patients not consenting or ineligible for allogeneic SCT or have refractory disease activity precluding allogemeoc SCT at this time, or
  • Patients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs.
  • ALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully controlled by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy).
  • Patients with ALL in hematologic remission after induction treatment, but ineligible for full execution of further standardly recommended treatments because of medical or other reasons.

Exclusion criteria

Exclusion Criteria:

  1. Subject received any of the following within the last 7 days of leukapheresis:

    • Any agent
    • Immunsupressive medication
    • Plasmapheresis
    • Major surgery (as defined by the investigator)
    • Radiation therapy other than local therapy for underlying
    • Use of any systemic anti-neoplastic drug therapy or immune suppressive medication applied for graft versus-host-disease or other, including the use of high dose e.g. >0,5 mg/kg BW methylprednisolone other than hydrocortisone replacement and other than intermittent topical, inhaled or intranasal corticosteroids which are allowed
  2. Subject has ≥ 3 at screening for inclusion in the trial
  3. Subject has clinical evidence of pulmonary leukostasis, disseminated intravascular coagulation or active graft versus-host-disease
  4. History or presence of CNS pathology such as epilepsy, seizure, paresis, aphasia, stroke, subarachnoid hemorrhage or other CNS bleed, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis
  5. Subject has any of the following laboratory abnormalities:

    • (ANC) \< 500/μL
    • count \< 50,000 mm3 (platelet transfusion allowed)
    • Serum (CrCl) \< 30 mL/min
    • Corrected serum calcium > 13.5 mg/dL (> 3.4 mmol/L)
    • Serum (AST) or alanine aminotransferase (ALT) > 2.5 × (ULN)
    • Serum total > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome or if part of disease involvement
    • International ratio () or partial thromboplastin time (PTT) > 1.5 × ULN, or history of Grade ≥ 2 hemorrhage within 30 days, or subject requires ongoing treatment with chronic, therapeutic dosing of anticoagulants (eg, warfarin, low molecular weight heparin, Factor Xa inhibitors)
  6. Patient has no adequate vascular access for leukapheresis
  7. Echocardiogram (ECHO) or multi-gated acquisition () with left ventricular ejection fraction \< 40%
  8. Patient with a history of Class III or IV congestive heart failure (CHF) or severe nonischemic cardiomyopathy, unstable or poorly controlled angina, myocardial infarction, or ventricular arrhythmia within the previous 3 months prior to starting study treatment
  9. Inadequate pulmonary function defined as oxygen saturation (Sa02) \< 90 % on room air
  10. Subject has history of primary immunodeficiency
  11. Subject is positive for (HIV-1), uncontrolled or C or active hepatitis A
  12. Subject with ongoing (incl. controlled) infections or infestations where inclusion of the patient into the clinical trials may significantly jeopardize the health and wellbeing of the patient, as determined by the investigator.
  13. Subject with malignancy other than the underlying malignancy in this protocol, unless this disease has been controlled for ≥ 1 year and the exception of the following noninvasive malignancies:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ of the cervix
    • Carcinoma in situ of the breast
    • Incidental histologic finding of prostate cancer (T1a or T1b using the TNM [tumor, nodes, ] clinical staging system) or prostate cancer that is curative
  14. Patient is a female who is pregnant, nursing, or breastfeeding, or who intends to become pregnant during participation in the study
  15. Patient with known to any component of MB-CART2219.1 product, cyclophosphamide, fludarabine, and/or tocilizumab
  16. Patient has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study
  17. Patient has any further condition including the presence of further laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (estimated)

Study arms

  • Experimental
    Dose finding

    Phase I dose finding and efficacy study using the 3+3 design

    Biological: CAR-T cells targeting CD19 and CD22

Interventions

  • BiologicalCAR-T cells targeting CD19 and CD22

    Using the 3+3 design, the following dose levels will be assessed: Dose level 1: 0.5x10e6 CAR-transduced T cells/kg; Dose level 2: 1x10e6 CAR-transduced T cells/kg; Dose level 3: 2x10e6 CAR-transduced T cells/kg; Dose level 0: 0.25x10e6 CAR-transduced T cells/kg

06

What researchers measure

Primary outcomes

  1. Safety and feasibility Phase I (CTCAE)

    Objective: to assess feasibility, safety of ex vivo generated MB-CART2219.1 in patients with relapsed or refractory CD19 and/or CD22 positive B cell malignancies. Determination of the recommended dose of MB-CART-CD19CD22, determined on the basis of the maximum tolerated dose, defined as the highest dose level of the 2-3 dose levels tested at which \<33% of patients experience DLT until d+28 after infusion of MBCART2219.1 and on the basis of the safety and efficacy data. Safety and toxicity assessment of MB-CART2219.1 per adverse events reporting classified according to CTCAE version 5.0 defined by \<33% of patients experiencing DLT, or maximal administered dose. The Trial uses two separate disease and age specific cohorts for dose escalation: cohort I (Lymphoma incl. CLL, adults) and cohort II (ALL, children). For each cohort in using the standard 3+3 design, three dose levels will be assessed. Feasibility will be defined as successful treatment without major deviation from the protocol

    Time frame: 6 months

07

Study locations

1 of 2 sites recruiting
  • University Hospital , Department of Internal Medicine II
    Tübingen, Baden-Wurttemberg 72076, Germany
    Recruiting
  • University Hospital, Clinic for Pediatric Medicine
    Tübingen, Baden-Wurttemberg 72076, Germany
    Not yet recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Mar 2027, 21 months after the start.

Of 138 non-industry phase 1 interventional studies under Lymphoma, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 88. This study's planned 21 months is below that.

Counting every sponsor, half of 280 studies reached it within 53 months; a quarter within 34 and three quarters within 77.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Aug 7, 2025
StartActual
Jun 23, 2025
Primary completionEst.
Mar 2027
CompletionEst.
Jun 2027
Last update
Nov 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
6 inclusion criteria edited, 26 added, 4 removed; 4 exclusion criteria edited, 1 removed
What changed in the criteria
Inclusion criteria
  • EditedFor Cohort II ALL, pediatricspediatric patients: Subject is ≥ 12-17 years of age at the time of signing ICF.
  • RemovedPatients with r/r lymphoma with following entities according to 5th edition of the WHO Classification of Haematolymphoid Tumors after two or more systemic therapies, including one approved in label CAR-T-cell or bispecific antibody treatment option or with contraindications for such treatments:
  • AddedCohort I: Lymphoma (Richter's Transformation /Burkitt lymphoma/NHL/CLL), Adults ≥18 years of age:
  • AddedDisease entities: Patients with relapsed or refractory (r/r) B-cell lymphoid malignancies according to the WHO Classification of Haematolymphoid Tumours (5th edition), including:
  • EditedB-lymphoblastic lymphomaslymphoma
  • EditedB-Chronic lymphocytic leukemia (CLL)
  • EditedDiffuse large B-cell lymphoma (DLBCL) / Large B-cell lymphoma
  • RemovedTransformation from indolent lymphoma
  • RemovedPatients with r/r CLL after established and approved treatment options including therapy with BTK inhibitors have failed
  • RemovedPatients with lymphoma recommended for autologous or allogeneic stem cell transplant (SCT) therapy by interdisciplinary boards, but not consenting or ineligible for this treatment (including patients with refractory disease precluding allo SCT at this time, which can be included in the study as bridge to allo SCT)
  • AddedTransformed indolent B-cell lymphoma (including Richter's transformation)
  • AddedPrior treatment and disease status: Patients must meet one of the following criteria:
  • AddedRelapsed or refractory disease after ≥2 prior systemic therapies, including at least one of the following (if clinically indicated and available):
  • AddedApproved CAR-T cell therapy, or
  • AddedBispecific antibody therapy OR
  • AddedContraindication to CAR-T cell therapy and/or bispecific antibody therapy
  • AddedCLL-specific: Patients with relapsed or refractory CLL:
  • AddedAfter failure of established and approved treatment options
  • AddedIncluding prior exposure to BTK inhibitor-based therapy
  • AddedTransplant-related eligibility: Patients fulfilling at least one of the following:
  • AddedIndication for autologous or allogeneic stem cell transplantation (SCT) as determined by a multidisciplinary board, but ineligible for SCT, or declining SCT after informed consent discussion
  • AddedPatients with refractory disease currently precluding alloSCT, including those considered for bridging to allogeneic SCT within the study framework
  • AddedPost-transplant or post-targeted therapy relapse: Patients meeting at least one of the following:
  • AddedRelapse following autologous or allogeneic SCT
  • AddedRelapse following CD19- or CD22-directed therapy
  • AddedConfirmed expression of CD19 or CD22 at relapse
  • AddedCentral nervous system (CNS) involvement
  • EditedPatients with CNS involvement by lymphoma are eligible if disease is successfully controlled at the time of inclusion
  • AddedProvided that CNS disease is adequately controlled at the time of study inclusion Or
  • AddedCohort II: Acute B-lymphoplastic Leukemia (B-ALL), pediatric patients aged ≥ 12 - 17 years:
  • AddedPatients with second or later relapse of ALL with >5% blasts in BM or rising molecular failure on two separate measurements and without an approved option for in label CAR-T cells or bispecific or cytotoxic antibody treatment.
  • EditedPatients with lymphoma relapse after SCT, or afterCD19other CD19 or CD22 targeting therapies andtargeted treatment with confirmed either CD19 or CD22 expression after relapse.
  • AddedPatients not consenting or ineligible for allogeneic SCT or have refractory disease activity precluding allogemeoc SCT at this time, or
  • AddedPatients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs.
  • AddedALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully controlled by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy).
  • AddedPatients with ALL in hematologic remission after induction treatment, but ineligible for full execution of further standardly recommended treatments because of medical or other reasons.
Exclusion criteria
  • EditedSubject has ECOG >≥ 3 at screening for inclusion in the trial
  • RemovedAbsolute lymphocyte count < 200/µL at time of leukapheresis
  • EditedSerum Creatinine Clearance (CrCl) < 4530 mL/min
  • EditedSerum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome or if part of disease involvement

…and 1 more changes, on the record history on ClinicalTrials.gov ↗

Nov 6, 2026
Contact
Study contact changed: P•••@med.uni-tuebingen.de · •••0894→T•••@med.uni-tuebingen.de · •••0894. See the current contact
Nov 6, 2026
Site contacts
Changed at 2 sites. See the sites
Show 2 sites
  • University Hospital , Department of Internal Medicine II · Tübingen, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
  • University Hospital, Clinic for Pediatric Medicine · Tübingen, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 6, 2026
Show all 1 update
  1. Nov 6, 2026
    Eligibility 6 inclusion criteria edited, 26 added, 4 removed; 4 exclusion criteria edited, 1 removed
    What changed in the criteria
    Inclusion criteria
    • EditedFor Cohort II ALL, pediatricspediatric patients: Subject is ≥ 12-17 years of age at the time of signing ICF.
    • RemovedPatients with r/r lymphoma with following entities according to 5th edition of the WHO Classification of Haematolymphoid Tumors after two or more systemic therapies, including one approved in label CAR-T-cell or bispecific antibody treatment option or with contraindications for such treatments:
    • AddedCohort I: Lymphoma (Richter's Transformation /Burkitt lymphoma/NHL/CLL), Adults ≥18 years of age:
    • AddedDisease entities: Patients with relapsed or refractory (r/r) B-cell lymphoid malignancies according to the WHO Classification of Haematolymphoid Tumours (5th edition), including:
    • EditedB-lymphoblastic lymphomaslymphoma
    • EditedB-Chronic lymphocytic leukemia (CLL)
    • EditedDiffuse large B-cell lymphoma (DLBCL) / Large B-cell lymphoma
    • RemovedTransformation from indolent lymphoma
    • RemovedPatients with r/r CLL after established and approved treatment options including therapy with BTK inhibitors have failed
    • RemovedPatients with lymphoma recommended for autologous or allogeneic stem cell transplant (SCT) therapy by interdisciplinary boards, but not consenting or ineligible for this treatment (including patients with refractory disease precluding allo SCT at this time, which can be included in the study as bridge to allo SCT)
    • AddedTransformed indolent B-cell lymphoma (including Richter's transformation)
    • AddedPrior treatment and disease status: Patients must meet one of the following criteria:
    • AddedRelapsed or refractory disease after ≥2 prior systemic therapies, including at least one of the following (if clinically indicated and available):
    • AddedApproved CAR-T cell therapy, or
    • AddedBispecific antibody therapy OR
    • AddedContraindication to CAR-T cell therapy and/or bispecific antibody therapy
    • AddedCLL-specific: Patients with relapsed or refractory CLL:
    • AddedAfter failure of established and approved treatment options
    • AddedIncluding prior exposure to BTK inhibitor-based therapy
    • AddedTransplant-related eligibility: Patients fulfilling at least one of the following:
    • AddedIndication for autologous or allogeneic stem cell transplantation (SCT) as determined by a multidisciplinary board, but ineligible for SCT, or declining SCT after informed consent discussion
    • AddedPatients with refractory disease currently precluding alloSCT, including those considered for bridging to allogeneic SCT within the study framework
    • AddedPost-transplant or post-targeted therapy relapse: Patients meeting at least one of the following:
    • AddedRelapse following autologous or allogeneic SCT
    • AddedRelapse following CD19- or CD22-directed therapy
    • AddedConfirmed expression of CD19 or CD22 at relapse
    • AddedCentral nervous system (CNS) involvement
    • EditedPatients with CNS involvement by lymphoma are eligible if disease is successfully controlled at the time of inclusion
    • AddedProvided that CNS disease is adequately controlled at the time of study inclusion Or
    • AddedCohort II: Acute B-lymphoplastic Leukemia (B-ALL), pediatric patients aged ≥ 12 - 17 years:
    • AddedPatients with second or later relapse of ALL with >5% blasts in BM or rising molecular failure on two separate measurements and without an approved option for in label CAR-T cells or bispecific or cytotoxic antibody treatment.
    • EditedPatients with lymphoma relapse after SCT, or afterCD19other CD19 or CD22 targeting therapies andtargeted treatment with confirmed either CD19 or CD22 expression after relapse.
    • AddedPatients not consenting or ineligible for allogeneic SCT or have refractory disease activity precluding allogemeoc SCT at this time, or
    • AddedPatients with Ph+ ALL if they are intolerant to tyrosine kinase inhibitor (TKI) therapy, or if they have r/r disease after treatment with at least 2 different TKIs.
    • AddedALL patients with combined bone marrow and CNS and/or testicular relapse are eligible only if the extramedullary disease has been successfully controlled by conventional therapy at the time of inclusion (e.g. intrathecal chemotherapy, orchiectomy).
    • AddedPatients with ALL in hematologic remission after induction treatment, but ineligible for full execution of further standardly recommended treatments because of medical or other reasons.
    Exclusion criteria
    • EditedSubject has ECOG >≥ 3 at screening for inclusion in the trial
    • RemovedAbsolute lymphocyte count < 200/µL at time of leukapheresis
    • EditedSerum Creatinine Clearance (CrCl) < 4530 mL/min
    • EditedSerum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome or if part of disease involvement

    …and 1 more changes, on the record history on ClinicalTrials.gov ↗

    Contact Study contact changed: P•••@med.uni-tuebingen.de · •••0894→T•••@med.uni-tuebingen.de · •••0894. See the current contact
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University Hospital , Department of Internal Medicine II · Tübingen, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
    • University Hospital, Clinic for Pediatric Medicine · Tübingen, GermanyContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07108868
Responsible party
Sponsor
First posted
Aug 7, 2025
Start date
Jun 23, 2025
Primary completion
Mar 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 6, 2026

Study contacts

Wolfgang Bethge, Prof. Dr.
Contact
Wolfgang.Bethge@med.uni-tuebingen.de
+49 7071 29-83176
Tim Flaadt, Dr.
Contact
Tim.Flaadt@med.uni-tuebingen.de
+49 7071 29-80894
Wolfgang Bethge, Prof. Dr.
principal investigator · University Hospital Tuebingen, Department of Internal Medicine II
Tim Flaadt, Dr.
principal investigator · University Hospital Tuebingen, Department of Pediatrics and Adolescent Medicine

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion